Drug Approval | February 16, 2023
Zydus receives tentative approval from the USFDA for Canagliflozin tablets
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Subscribe To Our Newsletter & Stay Updated
